Evaluation of combinations of CuDIPS, Tween 80 and cyclophosphamide as therapy for reticulum cell sarcoma in SJL/J mice.
Three agents, shown previously to have anticancer activity in the SJL/J tumor system, were tested in combinations for effects on survival rate and incidence of reticulum cell sarcoma at 52 weeks of age. Combined treatment with Cu(II)2(3,5-diisopropylsalicylate)4 (CuDIPS) and polyoxyethylenesorbitan monooleate (Tween 80) proved of no value. Indeed, inhibitory influence on tumorigenesis was diminished when Tween 80 was injected weekly at 24 hours or at 72 hours after weekly injections of CuDIPS. However, tumor incidence was reduced significantly, 90% (controls) to 7%, in mice treated weekly with cyclophosphamide (CY) at 24 hours after weekly injection of CuDIPS. Further, weekly administration of CY at 72 hours after weekly injection of Tween 80 resulted in a significant decrease in tumor incidence, 85% (controls) to 0%, and an increase in survival rate, 75% (controls) to 100%. Implications of these findings are discussed.
Crispens
C G
CG
Department of Biology, University of Alabama, Birmingham 35294.
Sorenson
J R
JR
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D051379:Mice; D008815:Mice, Inbred Strains; D011136:Polysorbates / Q000008:administration & dosage; D012459:Salicylates / Q000008:administration & dosage
D011136:Polysorbates; D012459:Salicylates; C030865:copper bis(3,5-diisopropylsalicylate); D003520:Cyclophosphamide